Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
BOSTON, April 03, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients...
-
ROUYN-NORANDA, Quebec, April 02, 2026 (GLOBE NEWSWIRE) -- Abcourt Mines Inc. ("Abcourt" or the "Company") (TSX Venture: ABI) (OTCQB: ABMBF) is pleased to announce that the TSX Venture Exchange...
-
Luxembourg City , April 01, 2026 (GLOBE NEWSWIRE) -- From the heart of Europe's financial center, StockIntent launches its global stock research platform, giving private investors access to tools...
-
To the Board of Directors of Xponential Fitness, Inc. (NYSE: XPOF): COCONUT CREEK, Fla., April 01, 2026 (GLOBE NEWSWIRE) -- Kanen Wealth Management, LLC, as owners of approximately 4% of the...
-
Total AVAX Holdings of Approximately 13,936,000 as of March 31, 2026 Completed 3.3 Million Share Repurchases Under $40 Million Share Repurchase Program WEST PALM BEACH, FL, March 31, 2026 (GLOBE...
-
Teladoc Health’s mental health platform is a Hidden Crown Jewel Calls on the Board to initiate Strategic Review and launch $200m+ share buyback
-
Dubai and New York, March 31, 2026 – VEON Ltd. (Nasdaq: VEON), a global digital operator, (“VEON” or the “Company”), today announced that its Board of Directors (the “Board”) has set the date for the...
-
CMD Generated $40.5 Million in 2025 Revenue, Representing 32% Year-Over-Year Growth Compared with CMD’s Full-Year 2024 Pro Forma Revenue, Which Reflects the Full Year of CMD Operations for...
-
AUSTIN, Texas, March 31, 2026 (GLOBE NEWSWIRE) -- via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce...
-
BASEL, Switzerland, March 31, 2026 (GLOBE NEWSWIRE) -- BioVersys strengthens its Ansamycin Chemistry platform and research on tackling difficult-to-treat non-tuberculous mycobacteria (NTM)...